ProKidney Corp. Class A PROK
NASDAQ · United States · Health Technology
$1.72+0.01 (+0.58%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Seven abstracts spanning CKD translational model studies and drug product characterization provide converging evidence supporting a multifactorial mechanism of action for rilparencelOne clinical abstract presents a new pooled Phase 2 analysis of patients meeting key PROACT 1 inclusion criteria that continues to indicate a strong safety profile and kidney function stabilization in patients with advanced CKD and type 2 diabetes mellitus WINSTON-SALEM, N.C., Oct. 02, 2026 (GLOBE NEWSWIRE) -- ProKid
On August 10, ProKidney Corp. (NASDAQ:PROK) reported second-quarter financial results that doubled as a status update on the biggest bet in its history: a cell therapy for chronic kidney disease that is now one step closer to a verdict. The clinical-stage company completed enrollment for the analysis that will decide whether its treatment gets an […]
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Completed enrollment of patients contributing to the Phase 3 PROACT 1 accelerated approval efficacy analysis, positioning the Company for anticipated pivotal eGFR slope topline results in Q2 2027On track for completion of full enrollment for PROACT 1 in the second half of 2026Appointed Kenneth Locke as Chief Technical Officer, adding more than 25 years of R&D, CMC and supply chain leadership experienceEnded Q2 2026 with $181.6 million in cash and cash equivalents and marketable securities, suppo
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.